Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 4, 2004, Pages 722-729

  Parrish, Nicole M ^a   Ko, Chiew G ^a   Hughes, Minerva A ^b   Townsend, Craig A ^b   Dick, James D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

2 D protein electrophoresis; Ethanol metabolism; Growth inhibition; Mycobacterial respiration; Mycolic acids

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALCOHOL; ANTIBIOTIC AGENT; ANTIMYCOBACTERIAL AGENT; BACTERIAL PROTEIN; CERULETIDE; DICOUMAROL; DICYCLOHEXYLCARBODIIMIDE; ENZYME INHIBITOR; ETHAMBUTOL; FATTY ACID SYNTHASE; HEAT SHOCK PROTEIN; ISONIAZID; METHIONINE; MYCOLIC ACID; N OCTANESULPHONYLACETAMIDE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE INHIBITOR; RIFAMPICIN; ROTENONE; STREPTOMYCIN; SULFUR 35; THENOYLTRIFLUOROACETONE; UNCLASSIFIED DRUG;

ARTICLE; BETA CHAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; ENERGY YIELD; GENE OVEREXPRESSION; IN VITRO STUDY; ISOTOPE LABELING; MACROMOLECULE; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RESPIRATORY CHAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STANDARD; TIME; TWO DIMENSIONAL ELECTROPHORESIS;

ACETAMIDES; ADENOSINE TRIPHOSPHATE; ALKANESULFONATES; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BACTERIAL PROTON-TRANSLOCATING ATPASES; ELECTRON TRANSPORT; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME INHIBITORS; HEAT-SHOCK PROTEINS; MYCOBACTERIUM BOVIS; MYCOLIC ACIDS; PROTEIN SUBUNITS;

EID: 6344249242     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh408     Document Type: Article

References (37)

1. Netto, E., Dye, C. & Raviglione, M. (1999). Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project. International Journal of Tuberculosis and Lung Disease 3, 310-20.
2. Centers for Disease Control and Prevention. (1993). Estimates of future global tuberculosis morbidity and mortality. MMWR Morbidity and Mortality Weekly Report 42, 961-4.
3. Centers for Disease Control and Prevention. (1996). Tuberculosis morbidity - United States 1995. MMWR Morbidity and Mortality Weekly Report 45, 365-70.
4. Centers for Disease Control and Prevention. (1998). Development of new vaccines for tuberculosis. Recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR Morbidity and Mortality Weekly Report: Recommendations and Reports 47, 1-6.
5. World Health Organization. Global Tuberculosis Control. WHO Report 2000. WHO/CDS/TB/2000 275. WHO, Geneva, Switzerland.
6. De Cock, K. & Chaisson, R. (1999). Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. International Journal of Tuberculosis and Lung Disease 3, 457-65.
7. Perlman, D., El-Helou, P. & Samomon, N. (1999). Tuberculosis in patients with human immunodeficiency virus infection. Seminars in Respiratory Infections 14, 344-52.
8. Dooley, S., Jarvis, W., Martone, W. et al. (1992). Multidrug-resistant tuberculosis. Annals of Internal Medicine 117, 257-9.
9. Frieden, T., Sterling, T., Pablos-Mendez, A. et al. (1993). The emergence of drug-resistant tuberculosis in New York City. New England Journal of Medicine 328, 521-6.
10. Pablos-Mendez, A., Raviglione, M., Laszlo, A. et al. (1998). Global surveillance for anti-tuberculosis-drug resistance, 1994-1998. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. New England Journal of Medicine 338, 1998, 1641-9.
11. Mitchison, D. A. (1992). The Garrod Lecture: Understanding the chemotherapy of tuberculosis, current problems. Journal of Antimicrobial Chemotherapy 29, 477-93.
12. World Health Organization-International Union Against Tuberculosis and Lung Disease. (1997-2000). Anti-Tuberculosis Drug Resistance in the World. Report No. 2. WHO-IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO/CDS/TB/2000.278. WHO-IUATLD, Geneva, Switzerland.
13. Fung-Tomc, J., Minassian, B., Kolek, B. et al. (2000). In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. Journal of Antimicrobial Chemotherapy 45, 437-46.
14. Ji, B., Lounis, N., Truffot-Pernot, C. et al. (1995). In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 39, 1341-4.
15. Miyazaki, E., Miyazaki, M., Chen, J. et al. (1999). Moxifloxacin (Bayer 12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy 43, 85-9.
16. Cynamon, M., Klemens, S., Sharp, C. et al. (1999). Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy 43, 1189-91.
17. Stover, C., Warrener, P., Van Devanter, D. et al. (2000). A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-6.
18. Jones, P., Parrish, N., Houston, T. et al. (2000). A new class of antituberculosis agents. Journal of Medicinal Chemistry 43, 3304-14.
19. Parrish, N., Townsend, C., Jones, P. et al. (2001). In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Antimicrobial Agents and Chemotherapy 45, 1143-50.
20. Mariani, F., Capelli, G., Riccardi, G. et al. (2000). Mycobacterium tuberculosis H37Rv comparative gene-expression analysis in synthetic medium and human macrophage. Gene 253, 281-91.
21. Colston, M. & Lee, Y. (1985). Measurement of ATP generation and decay in Mycobacterium leprae in vitro. Journal of General Microbiology 131, 3331-7.
22. Parrish, N. (1999). Characterization of fatty acid synthesis in mycobacteria as an approach to elucidate potential antimycobacterial chemotherapeutic agents, PhD Thesis. Johns Hopkins University, Baltimore, MD, USA.
23. Parrish, N., Kuhajda, F., Heine, H. et al. (1999). Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. Journal of Antimicrobial Chemotherapy 43, 219-26.
24. Mdluli, D., Slayden, R., Zhu, Y. et al. (1998). Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 280, 1607-10.
25. Beauvieux, M., Tissier, P., Couzigou, P. et al. (2002). Ethanol perfusion increases the yield of oxidative phosphorylation in isolated liver of fed rats. Biochimica et Biophysica Acta 1570 135-40.
26. Bettelheim, F. & March, J. (1991). Alcohols, phenols, ethers, and halides. In Advances in Enzymology (Bettelheim, F. & March, J. Eds), pp. 1-84. John Wiley and Sons, New York, USA.
27. 0 ATP synthase in Escherichia coli. FEBS Letters 429 201-6.
28. 1 ATP synthase. Journal of Biological Chemistry 274, 15598-604.
29. 0-ATPase forms an elongated dimer that interacts with the F1 sector. Journal of Biological Chemistry 267, 7630-6.
30. Dunn, S., McLachlin, D. & Revington, M. (2000). The second stalk of Escherichia coli ATP synthase. Biochimica et Biophysica Acta 1458, 356-63.
31. 1 ATP synthase from the cross-linking of subunits b and c in the Escherichia coli enzyme. Journal of Biological Chemistry 275, 31340-6.
32. 0-ATPase. Journal of Biological Chemistry 272, 21233-9.
33. 1-ATPase are phosphorylated in the inner mitochondrial membrane. Biochemical and Biophysical Research Communications 243, 664-8.
34. Stewart, G., Wernisch, L., Stabler, R. et al. (2002). Dissection of the heat-shock response in Mycobacterium tuberculosis using mutants and microarrays. Microbiology 148, 3129-38.
35. E: role in global gene expression and survival in macrophages. Molecular Microbiology 41, 423-37.
36. 1-ATPase biogenesis in mitochondria. Biochimica et Biophysica Acta 1555, 101-5.
37. Jakob, U., Muse, W., Eser, M. et al. (1999). Chaperone activity with a redox switch. Cell 96, 341-52.